Cancer statistics, 2012
- PMID: 22237781
- DOI: 10.3322/caac.20138
Cancer statistics, 2012
Abstract
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. A total of 1,638,910 new cancer cases and 577,190 deaths from cancer are projected to occur in the United States in 2012. During the most recent 5 years for which there are data (2004-2008), overall cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.6% per year in women. Over the past 10 years of available data (1999-2008), cancer death rates have declined by more than 1% per year in men and women of every racial/ethnic group with the exception of American Indians/Alaska Natives, among whom rates have remained stable. The most rapid declines in death rates occurred among African American and Hispanic men (2.4% and 2.3% per year, respectively). Death rates continue to decline for all 4 major cancer sites (lung, colorectum, breast, and prostate), with lung cancer accounting for almost 40% of the total decline in men and breast cancer accounting for 34% of the total decline in women. The reduction in overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of about 1,024,400 deaths from cancer. Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket.
Copyright © 2012 American Cancer Society, Inc.
Similar articles
-
Cancer statistics, 2013.CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17. CA Cancer J Clin. 2013. PMID: 23335087
-
Cancer statistics, 2010.CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. CA Cancer J Clin. 2010. PMID: 20610543
-
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36. doi: 10.3322/caac.20121. Epub 2011 Jun 17. CA Cancer J Clin. 2011. PMID: 21685461
-
Cancer statistics, 2004.CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29. doi: 10.3322/canjclin.54.1.8. CA Cancer J Clin. 2004. PMID: 14974761 Review.
-
Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99. doi: 10.1093/jnci/djg040. J Natl Cancer Inst. 2003. PMID: 12953083 Review.
Cited by
-
The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by _targeting FasL.Mol Oncol. 2013 Jun;7(3):334-45. doi: 10.1016/j.molonc.2012.10.011. Epub 2012 Nov 7. Mol Oncol. 2013. PMID: 23177026 Free PMC article.
-
Increased chemosensitivity via _targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer.J Biol Chem. 2013 Jun 7;288(23):16476-16483. doi: 10.1074/jbc.M112.448142. Epub 2013 Apr 22. J Biol Chem. 2013. PMID: 23609451 Free PMC article.
-
Variable metastatic potentials correlate with differential plectin and vimentin expression in syngeneic androgen independent prostate cancer cells.PLoS One. 2013 May 22;8(5):e65005. doi: 10.1371/journal.pone.0065005. Print 2013. PLoS One. 2013. PMID: 23717685 Free PMC article.
-
Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond.J Clin Oncol. 2012 Dec 1;30(34):4233-42. doi: 10.1200/JCO.2012.42.6114. Epub 2012 Oct 15. J Clin Oncol. 2012. PMID: 23071236 Free PMC article. Review.
-
Clinicopathologic significance of β-catenin and matrix metalloproteinase-2 expression in non-small cell lung cancer.Med Oncol. 2013 Mar;30(1):437. doi: 10.1007/s12032-012-0437-z. Epub 2013 Jan 5. Med Oncol. 2013. PMID: 23292837
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous